logo

For the Inventor, By the Inventor

Lexington, MA, United States of America

Synageva Biopharma Corporation


USPTO Granted Patents = 25

% Expired Patents = 80.0



Forward Citations = 101

Loading Chart...
Loading Chart...

30 inventors (with patents filed for the assignee):

goldMedal Alex J Harvey (17 out of 36 patents)

silverMedal Jeffrey C Rapp (12 out of 23 patents)

bronzeMedal Robert D Ivarie (10 out of 18 patents)

4.  Julie A Morris (9 out of 14 patents)

5.  Guodong Liu (9 out of 14 patents)

6.  Markley C Leavitt (3 out of 14 patents)

7.  Anthony Quinn (2 out of 14 patents)

8.  Robert Etches (2 out of 22 patents)

9.  Wen Zhou (2 out of 2 patents)

10.  Lei Zhu (2 out of 6 patents)

11.  Leandro Christmann (2 out of 8 patents)

12.  Pericles Calias (1 out of 29 patents)

13.  Michael F Concino (1 out of 27 patents)

14.  Alla Romashko (1 out of 4 patents)

15.  Paolo Martini (1 out of 21 patents)


Core Competencies:
Transgenic Chickens
Antibody Expression
Lysosomal Acid Lipase
Exogenous Proteins
Protein Production
Fusion Proteins
Nucleic Acid Constructs
Glycosylated Proteins
Avian Derived Antibodies
In Vivo Transfection
Ovalbumin Promoter
Cytoplasmic Injection

25 patents:

1. 9144229 - Tissue specific expression of antibodies in chickens (2015-09-29),
2. 8993729 - Tissue specific expression of antibodies in chickens (2015-03-31),
3. 8945542 - Methods for treating lysosomal acid lipase deficiency (2015-02-03),
4. 8846603 - NPP1 fusion proteins (2014-09-30),
5. 8815242 - Avian derived antibodies (2014-08-26),
6. 8663631 - Methods for treating lysosomal acid lipase deficiency in patients (2014-03-04),
7. 8563803 - Method of making protein in an egg of a transgenic chicken (2013-10-22),
8. 8519214 - Production of exogenous proteins in egg whites of transgenic chickens (2013-08-27),
9. 8507749 - Transgenic chickens producing exogenous protein in eggs (2013-08-13),
10. 8431770 - Method of producing sialytransferase-modified proteins (2013-04-30),
11. 8383399 - Nucleic acid construct having an ovalbumin promotor (2013-02-26),
12. 8372956 - Antibodies produced in a transgenic avian egg white (2013-02-12),
13. 8222032 - Cell lines and methods for producing proteins (2012-07-17),
14. 8124732 - Composition comprising isolated human CTLA4-Fc fusion protein produced in a transgenic chicken (2012-02-28),
15. 7875762 - Method of producing an exogenous protein in the egg of a chicken (2011-01-25),
Company Overview
Synageva Biopharma Corporation is a biopharmaceutical company based in Lexington, Massachusetts, specializing in the development of innovative therapies for rare diseases. The organization focuses on leveraging advanced biotechnology to create treatments that address unmet medical needs, particularly in the areas of enzyme replacement therapy and other novel approaches. With a commitment to improving patient outcomes, Synageva aims to transform the landscape of rare disease treatment through its cutting-edge research and development initiatives.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

Synageva Biopharma Corporation USPTO Patent Assignee Logo
25 Patents

#34 in Lexington, MA

#804 in Massachusetts

#13,350 in US

#25,681 in the World

Lexington, MA (US)
Lexington, MA, United States of America

Synageva Biopharma Corporation

Forward Citations = 101

30 inventors:

goldMedal Alex J Harvey (17 out of 36 patents)

silverMedal Jeffrey C Rapp (12 out of 23 patents)

bronzeMedal Robert D Ivarie (10 out of 18 patents)

4.  Julie A Morris (9 out of 14 patents)

5.  Guodong Liu (9 out of 14 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Synageva Biopharma Corporation. Retrieved from https://idiyas.com/company/synageva-biopharma

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…